Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Licensed RSV Vaccines in LTCF vs Community Older Adults
NCT06077149Phase 4Completed
- Sponsor
- University of Rochester
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of RSVpreF vaccine, GSK3003899A in respiratory syncytial virus infection (RSV), sponsored by University of Rochester. Started Nov 2023; status: completed.
02
Drugs
RSVpreF vaccineGSK3003899A
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06077149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06077149.